Skip to main content
Premium Trial:

Request an Annual Quote

Transgene, French Cancer Association ID'ing Targets for Cancer Biotherapies

NEW YORK (GenomeWeb News) – French biopharmaceutical firm Transgene today and the Ligue nationale contre le cancer, or the French league against cancer, today announced an agreement to identify membrane-specific targets from gene expression data in order to develop new oncology biotherapies.

The data was collected by Ligue from more than 4,800 tumors.

The Lique initiated a program in 2000 called Carte d'Identité des Tumeurs (CIT), or identity card of tumors, to analyze the genes and chromosomal alternations in several cancers in order to better diagnose disease and predict disease evolution. The program also hopes to improve the ability to predict response to therapy and to improve therapeutic follow-up.

CIT enables the identification of biomarkers associated with specific tumor-specific cellular mechanisms, and the Ligue and Transgene hope to accelerate the development of specific drugs for certain tumors, they said.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.